JP2015528020A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015528020A5 JP2015528020A5 JP2015525512A JP2015525512A JP2015528020A5 JP 2015528020 A5 JP2015528020 A5 JP 2015528020A5 JP 2015525512 A JP2015525512 A JP 2015525512A JP 2015525512 A JP2015525512 A JP 2015525512A JP 2015528020 A5 JP2015528020 A5 JP 2015528020A5
- Authority
- JP
- Japan
- Prior art keywords
- deuterium
- compound according
- compound
- hydrogen
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 229910052805 deuterium Inorganic materials 0.000 claims 12
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 150000001975 deuterium Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000000155 isotopic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261677307P | 2012-07-30 | 2012-07-30 | |
| US61/677,307 | 2012-07-30 | ||
| PCT/US2013/052721 WO2014022390A1 (en) | 2012-07-30 | 2013-07-30 | Deuterated ibrutinib |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015528020A JP2015528020A (ja) | 2015-09-24 |
| JP2015528020A5 true JP2015528020A5 (enExample) | 2016-08-25 |
| JP6261580B2 JP6261580B2 (ja) | 2018-01-17 |
Family
ID=48917743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015525512A Expired - Fee Related JP6261580B2 (ja) | 2012-07-30 | 2013-07-30 | 重水素化イブルチニブ |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9422295B2 (enExample) |
| EP (1) | EP2882751B1 (enExample) |
| JP (1) | JP6261580B2 (enExample) |
| KR (1) | KR20150038486A (enExample) |
| CN (1) | CN104507946A (enExample) |
| AU (1) | AU2013296627C9 (enExample) |
| BR (1) | BR112015001839A2 (enExample) |
| CA (1) | CA2879400A1 (enExample) |
| EA (1) | EA201590296A1 (enExample) |
| ES (1) | ES2682043T3 (enExample) |
| IN (1) | IN2015DN00598A (enExample) |
| MX (1) | MX2015001246A (enExample) |
| WO (1) | WO2014022390A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2682043T3 (es) | 2012-07-30 | 2018-09-18 | Concert Pharmaceuticals Inc. | Ibrutinib deuterado |
| CN105017256A (zh) * | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| CN103965201A (zh) * | 2014-04-30 | 2014-08-06 | 淮海工学院 | 一种合成依鲁替尼中间体4-氨基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-d]嘧啶的方法 |
| CN104945404B (zh) * | 2014-06-25 | 2018-09-14 | 广东东阳光药业有限公司 | 一种n-丙烯羰基哌啶衍生物的制备方法 |
| MA41350A (fr) * | 2015-01-14 | 2017-11-21 | Janssen Pharmaceutica Nv | Synthèse d'un inhibiteur de la tyrosine kinase de bruton |
| EP3257855B1 (en) * | 2015-02-12 | 2020-04-22 | Shanghai Dude Medical Science and Technology Co., Ltd. | Method for preparing ibrutinib |
| WO2016132383A1 (en) * | 2015-02-18 | 2016-08-25 | Mylan Laboratories Limited | Process for the preparation of ibrutinib |
| CN106146508A (zh) * | 2015-03-19 | 2016-11-23 | 浙江导明医药科技有限公司 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
| US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
| WO2016151438A1 (en) * | 2015-03-20 | 2016-09-29 | Sun Pharmaceutical Industries Limited | A process for the preparation of ibrutinib |
| US10561659B2 (en) | 2016-05-04 | 2020-02-18 | Concert Pharmaceuticals, Inc. | Treatment of hair loss disorders with deuterated JAK inhibitors |
| US11384062B2 (en) | 2017-04-04 | 2022-07-12 | Combiphos Catalysts, Inc. | Deuterated (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide |
| TW201922256A (zh) | 2017-10-27 | 2019-06-16 | 中國大陸商浙江導明醫藥科技有限公司 | 治療淋巴樣惡性疾病之方法 |
| CN109988175A (zh) * | 2019-04-28 | 2019-07-09 | 梯尔希（南京）药物研发有限公司 | 一种依鲁替尼-d5的制备方法 |
| CN114105990A (zh) * | 2020-08-31 | 2022-03-01 | 北京四环制药有限公司 | 一种伊布替尼的合成方法 |
| CN112876484B (zh) * | 2020-08-31 | 2022-06-28 | 绍兴舜邦医药科技有限公司 | 一种氘代依鲁替尼的制备方法 |
| CN112125913B (zh) * | 2020-10-29 | 2024-07-19 | 瑞阳制药股份有限公司 | 高纯度伊布替尼的合成方法 |
| WO2023284765A1 (zh) * | 2021-07-16 | 2023-01-19 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡唑类化合物及包含该化合物的组合物及其用途 |
| WO2024109676A1 (zh) * | 2022-11-21 | 2024-05-30 | 天津征程医药科技有限公司 | 具有btk抑制作用的吡唑并嘧啶衍生物 |
| WO2024109789A1 (zh) * | 2022-11-23 | 2024-05-30 | 天津瑞程健达医药科技有限公司 | 作为btk抑制剂的吡啶酰胺类化合物 |
| CN118307541A (zh) * | 2023-01-09 | 2024-07-09 | 天津济坤医药科技有限公司 | 氘代吡唑并嘧啶衍生物及其制备方法和药物组合物、结合物及应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2186371A1 (en) | 1994-03-25 | 1995-10-05 | Robert T. Foster | Enhancement of the efficacy of dihydropyridines by deuteration |
| US6221335B1 (en) | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6440710B1 (en) | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| PT1104760E (pt) | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios |
| DE10155018A1 (de) * | 2001-11-07 | 2003-07-10 | Berolina Drug Dev Ab Svedala | Deuterierte Pyrazolopyrimidinone sowie diese Verbindungen enthaltende Arzneimittel |
| TW200413273A (en) | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| JP2006219373A (ja) * | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体 |
| CN101309917B (zh) | 2005-10-06 | 2013-09-11 | 奥斯拜客斯制药有限公司 | 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂 |
| US7750168B2 (en) | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| JO2630B1 (en) | 2006-04-13 | 2012-06-17 | نوفارتيس ايه جي | Organic compounds |
| CA2661404A1 (en) | 2006-09-05 | 2008-03-13 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
| PT2201840E (pt) * | 2006-09-22 | 2012-02-14 | Pharmacyclics Inc | Inibidores da tirosina quinase de bruton |
| US9212285B2 (en) | 2012-02-08 | 2015-12-15 | Council Of Scientific & Industrial Research | Electronically conducting carbon and carbon-based material by pyrolysis of dead leaves and other similar natural waste |
| ES2682043T3 (es) * | 2012-07-30 | 2018-09-18 | Concert Pharmaceuticals Inc. | Ibrutinib deuterado |
-
2013
- 2013-07-30 ES ES13745554.9T patent/ES2682043T3/es active Active
- 2013-07-30 BR BR112015001839A patent/BR112015001839A2/pt not_active IP Right Cessation
- 2013-07-30 EP EP13745554.9A patent/EP2882751B1/en active Active
- 2013-07-30 WO PCT/US2013/052721 patent/WO2014022390A1/en not_active Ceased
- 2013-07-30 IN IN598DEN2015 patent/IN2015DN00598A/en unknown
- 2013-07-30 AU AU2013296627A patent/AU2013296627C9/en not_active Ceased
- 2013-07-30 MX MX2015001246A patent/MX2015001246A/es unknown
- 2013-07-30 CN CN201380040337.9A patent/CN104507946A/zh active Pending
- 2013-07-30 US US14/418,831 patent/US9422295B2/en active Active
- 2013-07-30 KR KR20157005220A patent/KR20150038486A/ko not_active Withdrawn
- 2013-07-30 EA EA201590296A patent/EA201590296A1/ru unknown
- 2013-07-30 CA CA2879400A patent/CA2879400A1/en not_active Abandoned
- 2013-07-30 JP JP2015525512A patent/JP6261580B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-27 US US15/220,642 patent/US9777009B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015528020A5 (enExample) | ||
| JP2014097964A5 (enExample) | ||
| JP2014515351A5 (enExample) | ||
| JP2013032389A5 (enExample) | ||
| BR112015001839A2 (pt) | ibrutinibe deuterado | |
| JP2015525207A5 (enExample) | ||
| GEP201706735B (en) | Kinase inhibitors | |
| JP2013537203A5 (enExample) | ||
| JP2013147496A5 (ja) | 有機金属錯体 | |
| JP2013542261A5 (enExample) | ||
| PH12015500294A1 (en) | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors | |
| JP2015522045A5 (enExample) | ||
| JP2013010749A5 (ja) | カルバゾール化合物 | |
| JP2016537478A5 (enExample) | ||
| JP2011518833A5 (enExample) | ||
| PH12014500164A1 (en) | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | |
| JP2016515561A5 (enExample) | ||
| JP2013100341A5 (enExample) | ||
| JP2015537020A5 (enExample) | ||
| JP2017514910A5 (enExample) | ||
| JP2014520248A5 (enExample) | ||
| JP2013102146A5 (ja) | 化合物 | |
| JP2015520770A5 (enExample) | ||
| MX2016002794A (es) | Compuestos antiproliferativos. | |
| GEP201706741B (en) | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |